Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Pollack et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d56e1a75589c71d767d3ac — DOI: https://doi.org/10.1056/nejmoa1707278

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Idarucizumab for Dabigatran Reversal· 2015 · 1,450 citations
2. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran· 2015 · 244 citations
3. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients· 2009 · 3,749 citations
4. Idarucizumab for dabigatran reversal· 2015 · 1,169 citations
5. Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate· 2008 · 652 citations